Omega Therapeutics, Inc. Announces Resignation of Michelle C. Werner as Member of the Board of Directors and the Nominating and Corporate Governance Committee

Market Closed –
|
5-day change | 1st Jan Change | ||
0.8400 USD |
+7.36% |
|
+1.22% | +12.66% |
December 31, 2024 at 05:30 pm EST
On December 30, 2024, Michelle C. Werner notified Omega Therapeutics, Inc. of her resignation as a member of the Board of Directors of the Company and the Nominating and Corporate Governance Committee of the Board, effective immediately.
Omega Therapeutics, Inc. Announces Resignation of Michelle C. Werner as Member of the Board of Directors and the Nominating and Corporate Governance Committee |
Dec. 31 |
CI |
Omega Therapeutics, Inc. Announces Board and Committee Changes |
Dec. 06 |
CI |
Raymond James Downgrades Omega Therapeutics to Market Perform From Outperform |
Nov. 15 |
MT |
Omega Therapeutics, Inc. Announces Chief Executive Officer Changes |
Nov. 14 |
CI |
Omega Therapeutics, Inc. Appoints Jennifer Nelson, Ph.D., as Chief Scientific Officer |
Nov. 14 |
CI |
Omega Therapeutics, Inc. Announces Successful Completion of Phase 1 Trial for Novel Epigenomic Controller |
Nov. 14 |
CI |
Omega Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 |
Nov. 14 |
CI |
Omega Therapeutics, Inc. Elects Robert L. Rosiello as Class I Director |
24-10-04 |
CI |
Omega Therapeutics, Inc.(NasdaqGS:OMGA) dropped from S&P Global BMI Index |
24-09-22 |
CI |
Omega Therapeutics, Inc. Announces Publication of Epigenomic Controller OTX-2002 Preclinical Data in Nature Communications |
24-09-17 |
CI |
Omega Therapeutics, Inc. Enters into Amended and Restated Shared Space Arrangement |
24-08-30 |
CI |
Omega Therapeutics, Inc. Announces Executive Changes |
24-08-14 |
CI |
Chardan Adjusts Price Target on Omega Therapeutics to $7 From $6, Maintains Buy Rating |
24-08-07 |
MT |
Omega Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024 |
24-08-06 |
CI |
Omega Therapeutics, Inc.(NasdaqGS:OMGA) dropped from Russell 2000 Growth Index |
24-06-30 |
CI |
Omega Therapeutics, Inc.(NasdaqGS:OMGA) dropped from Russell 2500 Index |
24-06-30 |
CI |
Omega Therapeutics, Inc.(NasdaqGS:OMGA) dropped from Russell 3000 Index |
24-06-30 |
CI |
Omega Therapeutics, Inc.(NasdaqGS:OMGA) dropped from Russell 2000 Index |
24-06-30 |
CI |
Omega Therapeutics, Inc.(NasdaqGS:OMGA) dropped from Russell 3000 Growth Index |
24-06-30 |
CI |
Omega Therapeutics, Inc.(NasdaqGS:OMGA) dropped from Russell Small Cap Comp Growth Index |
24-06-30 |
CI |
Omega Therapeutics, Inc.(NasdaqGS:OMGA) dropped from Russell 2000 Dynamic Index |
24-06-30 |
CI |
Omega Therapeutics, Inc.(NasdaqGS:OMGA) dropped from Russell 3000E Growth Index |
24-06-30 |
CI |
Omega Therapeutics, Inc.(NasdaqGS:OMGA) dropped from Russell Small Cap Completeness Index |
24-06-30 |
CI |
Omega Therapeutics, Inc.(NasdaqGS:OMGA) dropped from Russell 3000E Index |
24-06-30 |
CI |
Omega Therapeutics, Inc.(NasdaqGS:OMGA) dropped from Russell 2500 Growth Index |
24-06-30 |
CI |
OMGA: Dynamic Chart
Omega Therapeutics, Inc. is a clinical-stage biotechnology company, which is engaged in the development of a programmable epigenomic mRNA medicine to treat or cure a broad range of diseases. The Companyâs OMEGA platform has enabled it to identify and validate various DNA-sequence-based epigenomic, zip codes, associated with individual regulatory elements within Insulated Genomic Domains (IGDs). The Company designs and engineers its mRNA therapeutics, called epigenomic controllers, or ECs, to target EpiZips for precision epigenomic control. Its pipeline consists of programs that span oncology, regenerative medicine, and multigenic diseases including immunologic and cardiometabolic conditions. The Companyâs precision epigenomic control delivered by the OMEGA platform has therapeutic applicability and transformational potential, spanning across oncology, multigenic diseases including immunologic and cardiometabolic conditions, and regenerative medicine.
More about the company

Buy
Last Close Price
0.8400USD
Average target price
9.500USD
Spread / Average Target
+1,030.95%
Consensus
Quarterly revenue – Rate of surprise
link